Development of integrated AI digital health solutions to help patients better manage their cardiovascular health.
Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure.
Through the collaboration, AstraZeneca and Eko will explore accelerating the development of Eko algorithms, enhancing clinical trials with Eko technology and potentially building new heart failure detection solutions.
Heart failure is one of the leading causes of morbidity and mortality, affecting approximately 64 million people worldwide. Heart failure happens when the heart cannot pump enough blood into the body and is most commonly detected by echocardiogram imaging tests that are not normally conducted during a physical exam. Because of the limited access to echocardiography or other diagnostic tests, heart failure is frequently diagnosed late, making life-prolonging treatment more challenging. Heart failure remains as fatal as some of the most common cancers and is the leading cause of hospitalization for those over the age of 65, representing a significant clinical and economic burden.